Inicio › Cáncer de pulmón › Kentucky
Ensayos clínicos de Cáncer de pulmón en Kentucky
25 estudios sobre Cáncer de pulmón buscan participantes en Kentucky.
Ciudades en Kentucky
Texto oficial del estudio (inglés)
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center, Lexington
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07063745Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT06780098Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Baptist Health Corbin, Corbin
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutandoFase 3
Edades de 70 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06096844A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06312137Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04198766Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Elizabeth Healthcare Edgewood, Edgewood
- y 5 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Kentucky Chandler Medical Center, Lexington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06060613Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06712316Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06287775A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- University of Kentucky ( Site 0019), Lexington
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 oct 2026 · NCT06731907Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Baptist Health Hardin Cancer Center, Elizabethtown
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT06712355Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 2
18 Minutes · Todos los sexos · Actualizado el 9 oct 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Markey Cancer Center at Lexington Clinic, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT06616584A Study of ZW251 in Participants With Advanced Solid Tumors
- Norton Cancer Institute, Louisville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT07164313Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Louisville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 ago 2026 · NCT05433142EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 45 en adelante · Todos los sexos · Actualizado el 1 jul 2026 · NCT07186296Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Louisville, Louisville
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 26 jun 2026 · NCT04614103A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Louisville, Louisville
ReclutandoFase 1/2
Edades de 18 a 70 · Todos los sexos · Actualizado el 11 jun 2026 · NCT05361174Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT05642572Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
- University of Kentucky, Lexington
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 may 2026 · NCT06047301Precision Lung Cancer Survivorship Care Intervention
- Markey Cancer Center, Lexington
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 feb 2026 · NCT05857995A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT06778863Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
- Lexington VA Health Care System, Lexington
- Robley Rex VA Medical Center, Louisville
ReclutandoEstudio observacional
Edades de 29 a 85 · Todos los sexos · Actualizado el 13 nov 2024 · NCT06426628De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.